RCS - Ondine Biomedical - Steriwave Featured on CNBC’s Worldwide Exchange

Ondine Biomedical

10/09/2025 07:00

RNS Number : 7557Y

Ondine Biomedical Inc.

10 September 2025

 

10 September 2025

 

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine" or the "Company")

 

Steriwave Featured on CNBC's Worldwide Exchange

Ondine Biomedical Inc. (AIM: OBI), a Canadian life sciences company pioneering light-activated, non-antibiotic infection prevention therapies, announces that its Steriwave® nasal photodisinfection technology received international media attention when it was highlighted yesterday on CNBC's Worldwide Exchange by former President of Mexico, Vicente Fox.

During the interview, Mr. Fox emphasized the global need to address antibiotic resistance (AMR), particularly in combatting hospital-acquired infections and protecting healthcare workers. He underscored the urgent need for innovative, effective infection-prevention strategies like Steriwave, a cost effective, non-antibiotic therapy that does not generate resistance. He indicated that there is a critical role for light-activated antimicrobial technologies in combating the escalating global threat of multidrug-resistant infections, especially in developing nations where, for most people, access to medicine and healthcare is limited.

Dr. Nicolas Loebel, President and CTO of Ondine Biomedical, stated:

"We are pleased that Steriwave photodisinfection and the urgent issue of antimicrobial resistance were both spotlighted on CNBC's Worldwide Exchange. This recognition underscores our leadership advancing non-antibiotic infection-prevention solutions and our global mission to deliver simple solutions to combat complex multidrug-resistant infections."

As previously announced on August 11, 2025, President Fox is serving as Chair of the Light Against AMR Initiative, a strategic program co-sponsored by Ondine Biomedical and the International Photodynamic Association. The Light Against AMR Initiative is dedicated to accelerating the deployment of affordable, light-based infection control technologies in fast-growing, underserved, and emerging markets worldwide.

 

Enquiries:

Ondine Biomedical Inc.
www.ondinebio.com
Carolyn Cross, CEO
+1 604 669 0555
 or via Vane Percy & Roberts
Strand Hanson Limited (Nominated & Financial Adviser)
James Harris, Richard Johnson
+44 (0)20 7409 3494
Peel Hunt LLP (Broker & Joint Financial Advisor)
James Steel, Dr. Chris Golden
+44 (0)20 7418 8900
Vane Percy & Roberts (Media Contact)
Simon Vane Percy
+44 (0)77 1000 5910

 

 

Correction note: During the broadcast, Mr. Fox was introduced and at one point referred to himself as a member of Ondine's Board of Directors. This was in error. Mr. Fox is not a member of Ondine's Board.

 

 

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life sciences company and leader in light-activated antimicrobial therapies ('photodisinfection') for the prevention and treatment of infections, including those caused by multidrug-resistant organisms. Ondine has a pipeline of investigational products, based on its proprietary photodisinfection technology, in various stages of development.

Ondine's nasal photodisinfection system has a CE mark in Europe and is approved in Canada, Australia, Mexico and several other countries under the name Steriwave®. In the US, it has been granted Qualified Infectious Disease Product designation and Fast Track status by the FDA and is currently undergoing clinical trials for regulatory approval. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns and other indications.

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
NRAFIFFEAVIILIE